跳到正文
原文
Nature Medicine· Ben George·· 28 天前AI 评分43

AMPLIFY-7P II 期试验:mKRAS 突变胰腺癌淋巴结靶向疫苗主终点未达,但特定亚组显示无疾病生存获益

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

AI 导读

AMPLIFY-7P II 期随机试验评估淋巴结靶向肽疫苗治疗 mKRAS 突变胰腺癌患者,主要终点无疾病生存未达标。预设亚组分析显示,循环肿瘤 DNA 阴性且既往未接受放射治疗的患者在疫苗组获得显著的无疾病生存获益。

正文

Nature Medicine, Published online: 23 October 2026; doi:10.1038/s41591-026-04734-7

As presented at the ESMO Congress 2026, in a randomized phase 2 trial evaluating an off-the-shelf lymph node-targeting peptide vaccine in patients with mutated KRAS pancreatic cancer within 6 months of standard curative intent therapy, the primary endpoint of disease-free survival was not met, but prespecified subgroup analyses showed significant disease-free survival benefit in the vaccine arm for patients with circulating tumor DNA-negative disease and in those without prior radiation treatment.

来源:Nature Medicine · nature.com